Valacyclovir: approved and off-label uses for the treatment of herpes virus infections in immunocompetent and immunocompromised adults

Bibliography

• Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections, an evidence-based review. Arch Intern Med 2008;168:1137-44
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Johnson RW, Breuer J, Recommendations for the management of herpes zoster. Clin Infect Dis 2007;44:S1-26
   PubMed Web of Science ®Google Scholar
• De Clercq E, Field HJ. Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 2006;147:1-11
   PubMed Web of Science ®Google Scholar
• Fletcher CV, Englund JA, Edelman CK, Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. Antimicrob Agents Chemother 1991;35:938-43
   PubMed Web of Science ®Google Scholar
• Lowance D, Neumayer HH, Legendre CM, ; International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999;340:1462-70
   PubMed Web of Science ®Google Scholar
• Winston DJ, Yeager AM, Chandrasekar PH, Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis 2003;36:749-58
   PubMed Web of Science ®Google Scholar
• Talarico CL, Burnette TC, Miller WH, Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob Agents Chemother 1999;43:1941-6
   PubMedGoogle Scholar
• Brigden D, Whiteman P. The mechanism of action, pharmacokinetics and toxicity of acyclovir – a review. J Infect 1983;6:3-9
   PubMedGoogle Scholar
• Wang L, Schultz M, Weller S, Pharmacokinetics and safety of valacyclovir, an acyclovir prodrug, in geriatric volunteers with and without concomitant diuretic therapy (Abstract P16). J Am Geriatr Soc 1993;41(Suppl 10):SA23
   Google Scholar
• Weller S, Blum MR, Doucette M, Pharmacokinetics of the acyclovir prodrug valacyclovir, after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54:595-605
   PubMed Web of Science ®Google Scholar
• Perry CM, Faulds D. Valaciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpes virus infections. Drugs 1996;52:754-72
   PubMed Web of Science ®Google Scholar
• Hoshino Y, Katano H, Zou P, Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers. J Virol 2009;83:11857-61
   PubMed Web of Science ®Google Scholar
• Chatis PA, Crumpacker CS. Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother 1992;36:1589-95
   PubMed Web of Science ®Google Scholar
• Erlich KS, Mills J, Chatis P, Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989;320:293-6
   PubMed Web of Science ®Google Scholar
• Safrin A, Crumpacker C, Chatis P, ; AIDS Clinical Trials Group. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991;325:551-5
   PubMed Web of Science ®Google Scholar
• Schillinger JA, McKinney CM, Garg R, Seroprevalence of herpes simplex virus type 2 and characteristics associated with undiagnosed infection: New York City, 2004. Sex Transm Dis 2008;35:599-606
   PubMed Web of Science ®Google Scholar
• Spruance SL, Jones TM, Blatter MM, High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob Agents Chemother 2003;47:1072-80
   PubMed Web of Science ®Google Scholar
• Fife KH, Barbarash RA, Rudolph T, ; Valaciclovir International Herpes Simplex Virus Study Group. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. Sex Transm Dis 1997;24:481-6
   PubMed Web of Science ®Google Scholar
• Spruance SL, Tyring SK, DeGregorio B, A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med 1996;156:1729-35
   PubMed Web of Science ®Google Scholar
• Bodsworth NJ, Crooks RJ, Borelli S, ; International Valaciclovir HSV Study Group. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. Genitourin Med 1997;73:110-6
   PubMedGoogle Scholar
• Abudalu M, Tyring S, Koltun W, Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial. Clin Infect Dis 2008;47:651-8
   PubMed Web of Science ®Google Scholar
• Reitano M, Tyring S, Lang W, ; International Valaciclovir HSV Study Group. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J Infect Dis 1998;178:603-10
   PubMed Web of Science ®Google Scholar
• Patel R, Bodsworth NJ, Woolley P, ; International Valaciclovir HSV Study Group. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. Genitourin Med 1997;73:105-9
   PubMedGoogle Scholar
• Wald A, Selke S, Warren T, Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis 2006;33:529-33
   PubMed Web of Science ®Google Scholar
• Corey L, Wald A, Patel R, Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11-20
   PubMed Web of Science ®Google Scholar
• Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995;155:1605-9
   PubMed Web of Science ®Google Scholar
• Hanania MM, Brietstein D. Postherpetic neuralgia: a review. Cancer Invest 1997;15:165-76
   PubMed Web of Science ®Google Scholar
• Schmader K. Management of herpes zoster in elderly patients. Infect Dis Clin Pract 1995;4:293-9
   Web of Science ®Google Scholar
• Beutner KR, Friedman DJ, Forszpaniak C, Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39:1546-53
   PubMed Web of Science ®Google Scholar
• Baker D, Eisen D. Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies. Cutis 2003;71:239-42
   PubMed Web of Science ®Google Scholar
• Rooney JF, Starus SE, Mannix ML, Oral acyclovir to supress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial. Ann Intern Med 1993;118:268-72
   PubMed Web of Science ®Google Scholar
• Gilbert S, McBurney E. Use of valacyclovir for herpes simplex virus-1 (HSV-1) prophylaxis after facial resurfacing: a randomized clinical trial of dosing regimens. Dermatol Surg 2000;26:50-4
   PubMed Web of Science ®Google Scholar
• Amir J, Harel L, Smetana Z, Varsano I. Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study. BMJ 1997;314:1800-3
   PubMedGoogle Scholar
• Colin J, Prisant O, Cochener B, Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology 2000;107:1507-11
   PubMed Web of Science ®Google Scholar
• Aizman A, Johnson MW, Elner SG. Treatment of acute retinal necrosis syndrome with oral antiviral medications. Ophthalmology 2007;114:307-12
   PubMed Web of Science ®Google Scholar
• Hato N, Yamada H, Kohno H, Valacyclovir and prednisolone treatment for Bell’s palsy: a multicenter, randomized, placebo-controlled study. Otol Neurotol 2007;28:408-13
   PubMed Web of Science ®Google Scholar
• Engstrom M, Berg T, Stjernquist-Desatnik A, Prednisolone and valaciclovir in Bell’s palsy: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2008;7:993-1000
   PubMed Web of Science ®Google Scholar
• Lerner AM, Beqaj SH, Deeter RG, A six-month trial of valacyclovir in the Epstein–Barr virus subset of chronic fatigue syndrome: improvement in left ventricular function. Drugs Today (Barc) 2002;38:549-61
   PubMed Web of Science ®Google Scholar
• Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT. Valacyclovir treatment in Epstein–Barr virus subset chronic fatigue syndrome: thirty-six months follow-up. In Vivo 2007;21:707-13
   PubMed Web of Science ®Google Scholar
• Balfour HHJ, Hokanson KM, Schacherer RM, A virologic pilot study of valacyclovir in infectious mononucleosis. J Clin Virol 2007;39:16-21
   PubMed Web of Science ®Google Scholar
• Dickerson FB, Boronow JJ, Stallings CR, Reduction of symptoms by valacyclovir in cytomegalovirus-seropositive individuals with schizophrenia. Am J Psychiatry 2003;160:2234-6
   PubMed Web of Science ®Google Scholar
• Dickerson FB, Stallings CR, Boronow JJ, Double blind trial of adjunctive valacyclovir in individuals with schizophrenia who are seropositive for cytomegalovirus. Schizophr Res 2009;107:147-9
   PubMedGoogle Scholar
• Saral R, Burns WH, Prentice HG. Herpes virus infections: clinical manifestations and therapeutic strategies in immunocompromised patients. Clin Haematol 1984;13:645-60
   PubMedGoogle Scholar
• Bustamante CI, Wade JC. Herpes simplex virus infection in the immunocompromised cancer patient. J Clin Oncol 1991;9:1903-15
   PubMedGoogle Scholar
• Liesveld JL, Abboud CN, Ifthikharuddin JJ, Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients. Biol Blood Marrow Transplant 2002;8:662-5
   PubMedGoogle Scholar
• Warkentin DI, Epstein JB, Campbell LM, Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients. Ann Pharmacother 2002;36:1525-31
   PubMed Web of Science ®Google Scholar
• Tomblyn M, Chiller T, Einsele H, Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:1143-238
   PubMed Web of Science ®Google Scholar
• Glenny AM, Fernandez Mauleffinch LM, Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev 2009;21:CD006706
   Google Scholar
• Kusne S, Schwartz M, Breinig MK, Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis 1991;163:1001-7
   PubMedGoogle Scholar
• Pettersson E, Hovi T, Ahonen J, Prophylactic oral acyclovir after renal transplantation. Transplantation 1985;39:279-81
   PubMed Web of Science ®Google Scholar
• Seale L, Jones CJ, Kathpalia S, Prevention of herpes virus infections in renal allograft recipients by low-dose oral acyclovir. JAMA 1985;254:3435-8
   PubMed Web of Science ®Google Scholar
• Styczynski J, Reusser P, Einsele H, Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009;43:757-70
   PubMed Web of Science ®Google Scholar
• Drugs for non-HIV viral infections. Treat Guidel Med Lett 2005;3:23-32
   PubMedGoogle Scholar
• Boeckh M. Prevention of VZV using antiviral agents. Herpes 2006;13:60-5
   PubMedGoogle Scholar
• Egan JJ, Carroll KB, Yonan N, Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial. J Heart Lung Transplant 2002;21:460-6
   PubMed Web of Science ®Google Scholar
• Kalil AC, Freifeld AG, Lyden ER, Stoner JA. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS ONE 2009;4:e5512
   PubMed Web of Science ®Google Scholar
• Vusirikala M, Wolff SN, Stein RS, Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis. Bone Marrow Transplant 2001;28:265-70
   PubMed Web of Science ®Google Scholar
• Ljungman P, de La Camara R, Milpied N, Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002;99:3050-6
   PubMed Web of Science ®Google Scholar
• Sheffield JS, Hill JB, Hollier LM, Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial. Obstet Gynecol 2006;108:141-7
   PubMedGoogle Scholar
• Money D, Steben M, Society of Obstetric and Gynaecologists of Canada. SOGC clinical practice guidelines: guidelines for the management of herpes simplex virus in pregnancy. Int J Gynaecol Obstet 2009;104:167-71
   PubMedGoogle Scholar
• Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years’ experience with acyclovir. J Infect Dis 2002;186:S40-6
   PubMed Web of Science ®Google Scholar
• Feinberg JE, Hurwitz S, Cooper D, A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis 1998;177:48-56
   PubMed Web of Science ®Google Scholar
• Sheffield JS, Fish DN, Hollier LM, Acyclovir concentrations in human breast milk after valaciclovir administration. Am J Obstet Gynecol 2002;186:100-2
   PubMed Web of Science ®Google Scholar
• Zeng L, Nath CE, Blair EYL, Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. Antimicrob Agents Chemother 2009;53:2918-27
   PubMed Web of Science ®Google Scholar
• Spruance SL, Stewart JC, Rowe NH, Treatment of recurrent herpes simplex labialis with oral acyclovir. J Infect Dis 1990;161:185-90
   PubMed Web of Science ®Google Scholar
• Spruance SL, Bodsworth N, Resnick H, Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J Am Acad Dermatol 2006;55:47-53
   PubMed Web of Science ®Google Scholar
• Bryson YJ, Dillon M, Lovett M, Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N Engl J Med 1983;308:916-21
   PubMed Web of Science ®Google Scholar
• Loveless M, Sacks SL, Harris JRW. Famciclovir in the management of first episode genital herpes. Infect Dis Clin Pract 1997;6:S12-16
   Web of Science ®Google Scholar
• Reichman RC, Badger GJ, Mertz GJ, Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA 1984;251:2103-7
   PubMed Web of Science ®Google Scholar
• Sacks SL, Aoki FY, Diaz-Mitoma F, Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. JAMA 1996;276:44-9
   PubMed Web of Science ®Google Scholar
• Corey L, Bodsworth N, Mindel A, An update on short-course episodic and prevention therapies for herpes genitalis. Herpes 2007;14:5A-11A
   Google Scholar
• Aoki FY, Tyring S, Diaz-Mitoma F, Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2006;42:8-13
   PubMed Web of Science ®Google Scholar
• Lebreun-Vignes B, Bouzamondo A, Dupuy A, A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. J Am Acad Dermatol 2007;57:238-46
   PubMedGoogle Scholar
• Mertz GJ, Loveless MO, Levin MJ, Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Arch Intern Med 1997;157:343-9
   PubMed Web of Science ®Google Scholar
• Wood MJ, Ogan PH, McKendrick MW, Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 1988;85:79-83
   PubMed Web of Science ®Google Scholar
• Tying S, Barbarash RA, Nahlik JE, Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995;123:89-96
   PubMedGoogle Scholar
• Shafran SD, Tyring SK, Ashton R, Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol 2004;29:248-53
   PubMed Web of Science ®Google Scholar
• Baker DA, Blythe JG, Miller JM. Once daily valacyclovir hydrochloride for suppression of recurrent genital herpes. Obst et Gynecol 1999;94:103-6
   PubMed Web of Science ®Google Scholar